patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · small molecule
rilzabrutinib
Marketedupdated 2mo agoby $SNY Sanofi🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for autoimmune thrombocytopenic purpura and 10 investigational indications.
indications
investigational
Sickle Cell Disease
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
News(1)
- Sanofi MS drug rejected in US gets an endorsement in Europe<figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…biopharma_dive · 2mo ago
comments(0)
5-min edit window · permanent after that